Page B Pennell1, Jacqueline A French1, Ryan C May1, Elizabeth Gerard1, Laura Kalayjian1, Patricia Penovich1, Evan Gedzelman1, Jennifer Cavitt1, Sean Hwang1, Alison M Pack1, Maria Sam1, John W Miller1, Steffanie H Wilson1, Carrie Brown1, Angela K Birnbaum1, Kimford J Meador1. 1. From Brigham and Women's Hospital, Harvard Medical School, Boston (P.B.P.); New York University Comprehensive Epilepsy Center (J.A.F.) and Columbia University (A.M.P.), New York, and Northwell Health, Great Neck (S.H.) - both in New York; Emmes, Rockville, MD (R.C.M., S.H.W., C.B.); Northwestern University, Chicago (E. Gerard); the University of Southern California, Los Angeles (L.K.), and Stanford University, Palo Alto (K.J.M.) - both in California; the Minnesota Epilepsy Group, St. Paul (P.P.), and the University of Minnesota, Minneapolis (A.K.B.); Emory University School of Medicine, Atlanta (E. Gedzelman); the University of Cincinnati, Cincinnati (J.C.); Wake Forest University, Winston-Salem, NC (M.S.); and the University of Washington, Seattle (J.W.M.).
Abstract
BACKGROUND: Among women with epilepsy, studies regarding changes in seizure frequency during pregnancy have been limited by the lack of an appropriate nonpregnant comparator group to provide data on the natural course of seizure frequency in both groups. METHODS: In this prospective, observational, multicenter cohort study, we compared the frequency of seizures during pregnancy through the peripartum period (the first 6 weeks after birth) (epoch 1) with the frequency during the postpartum period (the following 7.5 months after pregnancy) (epoch 2). Nonpregnant women with epilepsy were enrolled as controls and had similar follow-up during an 18-month period. The primary outcome was the percentage of women who had a higher frequency of seizures that impaired awareness during epoch 1 than during epoch 2. We also compared changes in the doses of antiepileptic drugs that were administered in the two groups during the first 9 months of epoch 1. RESULTS: We enrolled 351 pregnant women and 109 controls with epilepsy. Among the 299 pregnant women and 93 controls who had a history of seizures that impaired awareness and who had available data for the two epochs, seizure frequency was higher during epoch 1 than during epoch 2 in 70 pregnant women (23%) and in 23 controls (25%) (odds ratio, 0.93; 95% confidence interval [CI], 0.54 to 1.60). During pregnancy, the dose of an antiepileptic drug was changed at least once in 74% of pregnant women and in 31% of controls (odds ratio, 6.36; 95% CI, 3.82 to 10.59). CONCLUSIONS: Among women with epilepsy, the percentage who had a higher incidence of seizures during pregnancy than during the postpartum period was similar to that in women who were not pregnant during the corresponding epochs. Changes in doses of antiepileptic drugs occurred more frequently in pregnant women than in nonpregnant women during similar time periods. (Funded by the National Institutes of Health; MONEAD ClinicalTrials.gov number, NCT01730170.).
BACKGROUND: Among women with epilepsy, studies regarding changes in seizure frequency during pregnancy have been limited by the lack of an appropriate nonpregnant comparator group to provide data on the natural course of seizure frequency in both groups. METHODS: In this prospective, observational, multicenter cohort study, we compared the frequency of seizures during pregnancy through the peripartum period (the first 6 weeks after birth) (epoch 1) with the frequency during the postpartum period (the following 7.5 months after pregnancy) (epoch 2). Nonpregnant women with epilepsy were enrolled as controls and had similar follow-up during an 18-month period. The primary outcome was the percentage of women who had a higher frequency of seizures that impaired awareness during epoch 1 than during epoch 2. We also compared changes in the doses of antiepileptic drugs that were administered in the two groups during the first 9 months of epoch 1. RESULTS: We enrolled 351 pregnant women and 109 controls with epilepsy. Among the 299 pregnant women and 93 controls who had a history of seizures that impaired awareness and who had available data for the two epochs, seizure frequency was higher during epoch 1 than during epoch 2 in 70 pregnant women (23%) and in 23 controls (25%) (odds ratio, 0.93; 95% confidence interval [CI], 0.54 to 1.60). During pregnancy, the dose of an antiepileptic drug was changed at least once in 74% of pregnant women and in 31% of controls (odds ratio, 6.36; 95% CI, 3.82 to 10.59). CONCLUSIONS: Among women with epilepsy, the percentage who had a higher incidence of seizures during pregnancy than during the postpartum period was similar to that in women who were not pregnant during the corresponding epochs. Changes in doses of antiepileptic drugs occurred more frequently in pregnant women than in nonpregnant women during similar time periods. (Funded by the National Institutes of Health; MONEAD ClinicalTrials.gov number, NCT01730170.).
Authors: Torbjörn Tomson; Dina Battino; Erminio Bonizzoni; John Craig; Dick Lindhout; Emilio Perucca; Anne Sabers; Sanjeev V Thomas; Frank Vajda Journal: Neurology Date: 2019-08-07 Impact factor: 9.910
Authors: Kimford J Meador; Page B Pennell; Ryan C May; Elizabeth Gerard; Laura Kalayjian; Naymee Velez-Ruiz; Patricia Penovich; Jennifer Cavitt; Jaqueline French; Sean Hwang; Alison M Pack; Maria Sam; Eugene Moore; Dominic M Ippolito Journal: Epilepsy Behav Date: 2018-05-03 Impact factor: 2.937
Authors: Arne Reimers; Grethe Helde; Noémi Becser Andersen; Dag Aurlien; Elisabeth Surlien Navjord; Kathrine Haggag; Jakob Christensen; Kari Mette Lillestølen; Karl Otto Nakken; Eylert Brodtkorb Journal: Epilepsy Res Date: 2018-05-04 Impact factor: 3.045
Authors: Cynthia L Harden; Jennifer Hopp; Tricia Y Ting; Page B Pennell; Jacqueline A French; W Allen Hauser; Samuel Wiebe; Gary S Gronseth; David Thurman; Kimford J Meador; Barbara S Koppel; Peter W Kaplan; Julian N Robinson; Barry Gidal; Collin A Hovinga; Andrew N Wilner; Blanca Vazquez; Lewis Holmes; Allan Krumholz; Richard Finnell; Claire Le Guen Journal: Epilepsia Date: 2009-05 Impact factor: 5.864
Authors: Ian R Mulrenin; Julian E Garcia; Muluneh M Fashe; Matthew Shane Loop; Melissa A Daubert; Rachel Peragallo Urrutia; Craig R Lee Journal: Expert Opin Drug Metab Toxicol Date: 2021-11 Impact factor: 4.481
Authors: P Emanuela Voinescu; Kurt D Pennell; Camden P Bay; Zachary N Stowe; Limin Peng; Cheryl A Frye; Kathleen Y Tang; Page B Pennell Journal: Epilepsy Res Date: 2021-09-25 Impact factor: 3.045
Authors: Sheela Toprani; Kimford J Meador; Chelsea P Robalino; Carrie Anne Brown; Abigail G Matthews; Elizabeth E Gerard; Patricia Penovich; Evan Gedzelman; Jennifer Cavitt; Sean T Hwang; Laura A Kalayjian; Maria Sam; Alison Pack; Page B Pennell Journal: Neurology Date: 2022-07-19 Impact factor: 11.800
Authors: Kimford J Meador; Zachary N Stowe; Carrie Brown; Chelsea P Robalino; Abigail G Matthews; Laura A Kalayjian; P Emanuela Voinescu; Elizabeth E Gerard; Patricia Penovich; Evan R Gedzelman; Jennifer Cavitt; Page B Pennell Journal: Neurology Date: 2022-08-17 Impact factor: 11.800
Authors: Raju Khatri; John K Fallon; Craig Sykes; Natasha Kulick; Rebecca J B Rementer; Taryn A Miner; Amanda P Schauer; Angela D M Kashuba; Kim A Boggess; Kim L R Brouwer; Philip C Smith; Craig R Lee Journal: Front Pharmacol Date: 2021-04-15 Impact factor: 5.810
Authors: Muluneh M Fashe; John K Fallon; Taryn A Miner; Jacqueline B Tiley; Philip C Smith; Craig R Lee Journal: Front Pharmacol Date: 2022-09-21 Impact factor: 5.988